Zobrazeno 1 - 10
of 3 997
pro vyhledávání: '"pegylated liposomal doxorubicin"'
Autor:
Moles E, Chang DW, Mansfeld FM, Duly A, Kimpton K, Logan A, Howard CB, Thurecht KJ, Kavallaris M
Publikováno v:
International Journal of Nanomedicine, Vol Volume 19, Pp 3623-3639 (2024)
Ernest Moles,1– 4 David W Chang,1– 3 Friederike M Mansfeld,1– 3 Alastair Duly,1,2 Kathleen Kimpton,1 Amy Logan,1– 4 Christopher B Howard,5 Kristofer J Thurecht,5,6 Maria Kavallaris1– 4 1Children’s Cancer Institute, Lowy Cancer Research Ce
Externí odkaz:
https://doaj.org/article/b87c3605ba5d4417a67bb7d9cf141e21
Autor:
Suying Lu, Juan Wang, Junting Huang, Feifei Sun, Jia Zhu, Yi Que, Hui Li, Ying Guo, Ruiqing Cai, Zijun Zhen, Xiaofei Sun, Yizhuo Zhang
Publikováno v:
EClinicalMedicine, Vol 73, Iss , Pp 102701- (2024)
Summary: Background: The combined vincristine, pegylated liposomal doxorubicin (PLD), and cyclophosphamide (VPC) regimen has never been studied in pediatric patients. Methods: This open-label, single-center, single-arm phase I study utilizing a “3
Externí odkaz:
https://doaj.org/article/f8ea1d0acb6049e59316bb72b5272a62
Autor:
Wulipan Fulati, Jiexian Ma, Min Wu, Wensi Qian, Pingping Chen, Yingwei Hu, Mingyue Chen, Yu Xu, Zilan Huang, Hongdi Zhang, Yanhui Xie, Lin Shen
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThere was little evidence of autologous stem cell transplantation (ASCT) as consolidation therapy after remission of induction for patients with Peripheral T-cell lymphoma (PTCL). In this study, we conducted a comparative analysis of real-w
Externí odkaz:
https://doaj.org/article/71b0239115fa4a17a8e5582ea9059405
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Carboplatin/pegylated liposomal doxorubicin/bevacizumab is an accepted standard anti-cancer treatment option for recurrent ovarian cancer. However, the occurrence of adverse events associated with this therapeutic regimen limits its continued clinica
Externí odkaz:
https://doaj.org/article/8ae522dd2d4648dd8fd8f5524f85b308
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hiroyuki Yoshida, Keiichi Fujiwara
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 14196-14206 (2023)
Abstract Background Pegylated liposomal doxorubicin (PLD), an anthracycline agent, is widely used as a treatment option for platinum‐refractory/resistant epithelial ovarian cancer (EOC). Although only a subset of patients with platinum‐refractory
Externí odkaz:
https://doaj.org/article/3a63270ac62343279985571fa0c0bc2f
Publikováno v:
Cancer Medicine, Vol 12, Iss 12, Pp 13388-13396 (2023)
Abstract Purpose Real‐world data about pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC) are limited. We have aimed to highlight the role of PLD in daily practice focusing on older patients and patients with como
Externí odkaz:
https://doaj.org/article/10883d6fa71a4a53baab3fbb122d8220
Autor:
Li Li, Rongrong Chen, De Zhou, Jianai Sun, Lulu Wang, Lixia Zhu, Huafei Shen, Wanzhuo Xie, Xiujin Ye
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4184-4194 (2023)
Abstract Objectives In order to explore the impact of pegylated liposomal doxorubicin (PLD) dose intensity on survival outcomes of newly diagnosed elderly patients with diffuse large B‐cell lymphoma (DLBCL), we performed a retrospective study to co
Externí odkaz:
https://doaj.org/article/770beef4d5894fba88c6c2312a2ece14
Autor:
Saba Dadpour, Amin Mehrabian, Mahdieh Arabsalmani, Elaheh Mirhadi, Anis Askarizadeh, Mohammad Mashreghi, Mahmoud Reza Jaafari
Publikováno v:
IET Nanobiotechnology, Vol 16, Iss 7-8, Pp 259-272 (2022)
Abstract The size of nanoliposome‐encapsulated drugs significantly affects their therapeutic efficacy, biodistribution, targeting ability, and toxicity profile for the cancer treatment. In the present study, the biodistribution and anti‐tumoral a
Externí odkaz:
https://doaj.org/article/976762e36fb642269d4acca83f69b3d4
Publikováno v:
Journal of Ovarian Research, Vol 15, Iss 1, Pp 1-8 (2022)
Abstract Pegylated liposomal doxorubicin (PLD) is a nano-doxorubicin anticancer agent. It was used as early as 2014 to treat ovarian and breast cancer, multiple myeloma and Kaposi's sarcoma. The 2018 National Comprehensive Cancer Network guidelines l
Externí odkaz:
https://doaj.org/article/9a4e083bf4c741bb841f8a7e6d8b8f1d